Sumitomo’s novel AML candidate has shown early clinical promise and been granted US Fast Track status for a form of AML, which looks set to aid the Japanese firm's strategic shift to oncology following recent CNS setbacks. 

An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs. The earlier stage pipeline boasts a range of mechanistic approaches. 

Adding Oxford to its roster will help Apollo widen its net for potential first-in-class therapies, and connects with the university’s ambition to build world-beating spin-outs.

J&J topped the league table for CEO pay in 2023, a position it has held for three of the four past years. Meanwhile, the two companies that arguably generated the most buzz in 2023 neatly depict the stark contrast between the US and Europe when it comes to executive remuneration.